Thursday - November 6, 2025
FDA Issues Warning Letter to Aytu Biopharma
September 17, 2025
WASHINGTON, Sept. 17 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Aytu Biopharma from the Center for Drug Evaluation and Research:

* * *

Recipient: Josh Disbrow, Chief Executive Officer, Aytu Biopharma, 7900 E. Union Avenue, Suite 920, Denver, CO 80237, United States

Issuing Office: Center for Drug Evaluation and Research (CDER), United States

WARNING LETTER

. . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products